We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cesca Therapeutics Inc | NASDAQ:KOOL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.14 | 3.30 | 5.22 | 0 | 00:00:00 |
RANCHO CORDOVA, Calif., Oct. 24, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET.
Management will also be available for one-on-one meetings with qualified investors. Interested parties can register and request meetings through the Dawson James conference portal or contact Rx Communications to schedule a meeting.
A live webcast of the presentation will be available on Cesca Therapeutics' website at http://investors.cescatherapeutics.com/events-and-presentations/events. An archived replay will be available for a period of 90 days after the conference.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed a semi- automated, functionally closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca and ThermoGenesis, please visit: www.cescatherapeutics.com.
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-dawson-james-securities-5th-annual-small-cap-growth-conference-300943746.html
SOURCE Cesca Therapeutics Inc.
Copyright 2019 PR Newswire
1 Year Cesca Therapeutics Chart |
1 Month Cesca Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions